Objective: Changes in nutritional strategies over the past decade have been shown to improve postnatal growth in extremely low birth weight (ELBW) infants. We showed 10 years ago that the majority of these ELBW infants with bronchopulmonary dysplasia (BPD) suffer postnatal growth failure. We theorized that recent changes in nutritional support strategies would positively affect growth outcomes in ELBW infants with BPD.
Introduction
Postnatal growth failure is one of the most frequent morbidities in extremely low birth weight (ELBW) infants (birth weight p1000 g).
1,2 ELBW infants who develop bronchopulmonary dysplasia (BPD) are even more likely to develop postnatal growth failure secondary to the shunting of energy towards their respiratory needs, intercurrent illnesses, fluid restriction, diuretics and postnatal steroid use. 3 The etiology of BPD is multifactorial, but poor nutrition and postnatal growth failure are contributors. 4, 5 Early parenteral amino-acid administration improves postnatal growth and decreases extrauterine growth restriction (EUGR). [6] [7] [8] Matching the catabolic rate of protein prevents negative protein balance. Studies have shown that achieving close to 3 g kg À1 per day of protein shortly after birth decreases postnatal weight loss, leads to an earlier return to birth weight and improves weight at 36 weeks postmenstrual age. 9 Initiation of early enteral feeds (minimal enteral nutrition), reaching adequate enteral intakes earlier, expanded use of human milk and reducing duration of total parenteral nutrition (TPN) are also beneficial. [10] [11] [12] [13] Parenteral supplemental vitamin A to decrease BPD is used at many institutions. 14 Recently, calorically dense products, with an increased protein-to-energy ratio, have become available for fluid-restricted infants.
Recent studies have linked inadequate nutrition to poor neurodevelopmental outcomes, as evidenced by low head circumference growth and neurodevelopmental impairment at a critical time in early childhood. 15, 16 These data stress the importance of achieving optimal nutrition and postnatal growth, which may have implications later into adulthood. 17 ELBW infants with BPD are a group of babies at high risk for growth faltering. The goal set by the American Academy of Pediatrics Committee on Nutrition is to match the fetal growth rate of 15 g kg À1 per day while in the neonatal intensive care unit. 18 Historically, achieving this goal has been a challenge and we previously showed 10 years ago that the majority of these infants grew below fetal rate and suffered postnatal growth failure. 19 We hypothesized that recent changes in nutritional support (that is, earlier initiation of IV amino acids, minimal enteral nutrition and use of caloric-dense milk) would positively affect growth outcomes in ELBW infants with BPD.
Methods

Sample
A retrospective chart review was performed evaluating babies with birth weight (BW) p1000 g from three hospitals in Louisville, KY from 1 June 2006 to 31 December 2008. The University of Louisville Institutional Review Board approved this study. In all, 146 babies were eligible for the study based on birth weight and diagnosis of BPD; of those 58 were excluded secondary to medical/surgical NEC (30), diagnosis of hydrocephalus (24) , congenital defects (2) and infants who were discharged more than 8 months from birth (2) . Diagnosis of BPD at discharge and BW were the principle elements to inclusion.
Diagnosis of BPD required at least 28 days of oxygen therapy above FiO 2 of 0.21, and severity was assigned as mild (room air), moderate (FiO 2 <0.3) or severe (FiO 2 X 0.3 or requiring positive pressure ventilation) based on their FiO 2 requirement at 36 weeks post-menstrual age or discharge, whichever came first. 3 Growth rates (g kg À1 per day) were calculated from return to birth weight (RTBW) to discharge, based on the report from the National Institute of Child Health and Human Development. 1 Subsequently, three growth rate cohorts were constructed: less than fetal (p14 g kg À1 per day), approximate fetal (14.1 to 16 g kg À1 per day) and greater than fetal (X16.1 g kg À1 per day).
Data
Demographic data included gestational age (GA), birth weight and SNAPPE-II scores at birth. 20 Daily nutritional intake was documented including total days of TPN therapy, days to reach 100 and 120 kcal kg À1 per day enteral energy intake, as well as average protein intake (enteral and parenteral) during the first 20 days of life. RTBW was defined as the first day birth weight was regained and maintained for 3 consecutive days. Daily weight gained (g kg À1 per day) was calculated by taking a 7-day delta of weight gain (g) divided by 7 (days) and then divided by that first weight (kg). Weekly growth rates were averaged beginning with infant's RTBW up to first 110 days of life. Weekly head circumference growth (HC) was recorded and averaged over first 110 days of life beginning with RTBW. Small for gestational age for weight (SGA WT ) and HC (SGA HC ) at birth were defined as <10th percentile. 21 Extrauterine growth restriction for weight (EUGR WT ) and HC (EUGR HC ) at discharge were defined as <10th percentile for GA. 22 Use of calorically dense milk was defined as consumption of milk that was more than 24 kcal per oz for X7 days and included formula and human milk/formula mixtures.
Medications noted included rounds of antibiotics (administered for more than 3 consecutive days), days of dopamine and/or dobutamine over hospital course, total number of doses of furosemide throughout hospital stay, total number of doses of indomethacin and ibuprofen (not used for prophylaxis), total doses of systemic corticosteroids over hospital course (either for blood pressure or BPD) and doses of artificial surfactant (Survanta (Abbott Products, Columbus, OH, USA)). We also noted when chronic diuretic therapy (spironolactone and chlorothiazide) was required for more than 2 consecutive weeks. Respiratory support was recorded as days of mechanical ventilation and days of supplemental oxygen therapy above FiO 2 of 0.21. We noted co-morbidities such as ligation of patent ductus arteriosus and retinopathy of prematurity stage 3 or requiring laser surgery. A comparison was made between ELBW infants with BPD in our current data and ELBW infants with BPD in our previously published manuscript 19 from 1997 to 2000.
Analysis
Data were analyzed using SPSS (v 14). Continuous variables were tested with analysis of variance and the categorical variables were tested with Pearson's chi-square with statistical significance less than 0.05. Comparisons between our historical cohort and current study were analyzed by T-test for independent groups. Post-hoc hierarchical multiple regressions were conducted using continuous variables.
Results
Descriptive data are summarized in Table 1 . GA, BW, SGA WT and SGA HC were not different among the three cohorts. The infants with the higher SNAPPE-II scores at birth tended to grow the slowest and this was significant between the two growth extremes (P ¼ 0.046). Postnatal steroid exposure was not different between the three groups. Cohort 1 (less than fetal growth rate) received more systemic pressor agents, doses of surfactant and diuretic medication compared with cohort 3. Additionally, infants in cohort 1, on average, were diagnosed with more severe retinopathy of prematurity compared with cohort 3. There were no differences among the cohorts with regard to medical and surgical treatment of patent ductus arteriosus. Nutritional outcome data are summarized in Table 2 . Day of life nadir, percent weight loss from birth weight and RTBW were not significantly different. Weight gain was significant across all three cohorts (P<0.001), as anticipated with the study design. After comparing growth status at birth and at discharge (SGA and EUGR), we detected a 5.5-fold increase in growth restriction for infants in cohort 1 compared with a twofold increase for infants in cohorts 2 and 3. HC growth was also significant across all three groups (P<0.002). EUGR HC was statistically higher in cohor 1 versus 2 and 3. There was significant HC catch up growth in cohorts 2 and 3. Cohort 1 required more days of TPN than cohort 2 and 3. The 20-day amino-acid intakes trended up with the higher weight gaining groups. Finally, cohorts 2 and 3 reached full feeds sooner than cohort 1 (Pp0.004). No difference in the age at initiation of enteral nutrition was seen. Weight at discharge was higher in cohorts 1 and 2 despite equivalent BW and GA, but these infants had increased length of stay of 3 and 2 weeks than cohort 3, respectively. Of note, no statistical difference was seen among the three groups with weight at 36 weeks postmenstrual age. The vast majority of infants received calorically dense feedings (73%) at some point in their hospitalization. Respiratory outcome data (Table 3) shows that cohort 1 required the most days of supplemental oxygen and days of assisted mechanical ventilation. Cohort 3 had more infants with mild BPD (p0.002) compared with the other cohorts. In all, 65% of the infants with moderate BPD and 64% of the infants with severe BPD grew at or above fetal rates. Table 4 provides 10-year comparison data from infants diagnosed with BPD (1997 to 2000 group A) and the current study infants (group B). The birth weights and GA were comparable. Group B returned to BW sooner and had less postnatal weight loss than did the older cohort. Initiation of amino acid and enteral feedings occurred earlier and advanced to full feeds was more rapid in the current population. The infants in the current study weighed 291 g more at 36 weeks postmenstrual age and 370 g more at discharge, while staying 13 days less in the hospital than group A. After analyzing growth restriction by weight from birth to discharge, there was an eightfold increase in group A compared with only an 2.8-fold increase in group B. Likewise, comparing HC from birth to discharge, there was subnormal head growth in group A compared with group B.
Linear regression, including weight gain as the dependent variable and controlling for days of TPN was performed, post hoc based on previous findings. The number of days on TPN was entered into block 1 of the equation. The model was significant (P<0.001) and accounted for 20.1% of the variance in weight gain. In block 2, days to reach 120 kcal kg À1 per day and first 20-day amino-acid intake were added into this model, which remained significant (P ¼ 0.004) and accounted for an additional 10% of the variance. Only the first 20-day amino-acid intake (b ¼ 0.266, P ¼ 0.011) significantly predicted weight gain when all variables were in the model.
Discussion
BPD presents a challenge in regards to nutrition and growth for ELBW infants. These infants expend considerable amounts of energy to maintain their metabolic rate, synthesize new tissue and support the increased work of difficult respiration, physical activity and thermoregulation. 23 Difficulty in meeting their nutritional requirements in lieu of fluid balance concerns and other co-morbid conditions have been responsible for postnatal growth failure. Almost 10 years ago, we showed that ELBW infants with BPD grew less than fetal rate versus those without BPD who grew at fetal rate 19 and this is consistent with other studies. 1, 24 In the updated review, we were surprised to find that 73% of our ELBW infants with BPD grew at or above the fetal growth rate.
We speculate that the improvement in weight gain is multifactorial but would include use of calorically dense (>24 kcal per oz) milk products that maximize protein provision in fluid restricted infants. In this study, 73% of our infants received caloricdense milk during their stay, and 82% were in the first two cohorts. Current calorically dense milk delivers about 3 g of protein per 100 kcal in contrast to the milks of a decade ago, which contained about 2 g of protein per 100 kcal. The reduced postnatal weight loss and days required to RTBW are consistent with improvements associated with early aggressive nutrition, as evidenced by the earlier initiation of TPN and enteral feeds in group B (2006 to 2008).
The amount of protein these infants received in the first 20 days of life increased with the higher weight-gaining cohorts. These findings are supported with the linear regression model. The infants who grew above the fetal rate received 0.33 g kg À1 per day more than those who grew less than fetal rate. The infants that grew with greater velocity and received more protein in the first 20 days of life also had better head circumference growth. This is consistent with previous data. 25 Although we did not evaluate neurodevelopmental outcome, the findings of more protein received in the first weeks of life has been shown to improve cognitive development scores at 18 months of age. 26 We speculate that cohort 1 received less protein because they were more ill, which is consistent with higher SNAPPE-II scores, need for more respiratory support, more surfactant and greater use of diuretic medication. The SNAPPE-II scores, which reflect the degree of illness at birth, were highest in the infants who subsequently demonstrated postnatal growth failure and who ultimately had the highest incidence of severe BPD. We did observe more days of supplemental oxygen and days of mechanical ventilation with poor growth. To our knowledge there are no reported studies linking SNAPPE-II scores as a predictor for postnatal growth failure. Future studies may determine whether a relationship exists between SNAPPE-II scores and postnatal growth failure. Surprisingly, at 36 weeks postmenstrual age there were no differences in weight, the age at which the NICHD defines postnatal growth failure (weight less than 10th percentile for GA). These data suggest that it is important to follow growth rates during this period for changes in growth trajectory as it may be a period of especially important catch-up growth, as seen in the infants who grew at or above fetal rate. This finding is important because of the association of suboptimal nutrition and decrease head growth with poor long-term neurodevelopmental outcome. 15, 27 The number of infants with HC<10th percentile almost doubled from birth to discharge in those babies who grew less than fetal rate. A similar comparison was found looking at the infants with BPD in the 1997 to 2000 epoch. This is consistent with other studies linking BPD with poor neurodevelopmental outcome. 28, 29 We have shown that infants with BPD in the current era have improved growth and can demonstrate catch-up growth for weight and HC compared with 10 years ago. We speculate that the use of early parenteral amino acids and caloric-dense feeding strategies had a significant role.
